Arcutis (ARQT) Q4 2025 earnings review
Explosive ZORYVE Sales Drive Arcutis to Consistent Profitability
Arcutis delivered a breakout quarter, thoroughly shedding its cash-burning biotech status. ZORYVE net product revenue surged 84% YoY to $127.5M, driving the company to a $17.4M net income—a stark reversal from a $10.8M loss a year ago. Operating cash flow also turned firmly positive at $26.2M. With momentum building, management confidently raised 2026 revenue guidance to a midpoint of $487.5M. The only major structural shift is the termination of the Kowa partnership; Arcutis will now take full control of primary care sales, introducing new execution risks but offering better long-term margin control.
🐂 Bull Case
The company generated $26.2M in operating cash flow in Q4 and expects to maintain positive quarterly cash flow going forward, eliminating the need for dilutive equity raises.
Q4 product revenue accelerated 29% sequentially. Gross-to-net pricing improved, and new Medicare access starting in January 2026 provides a fresh catalyst for volume growth.
🐻 Bear Case
Terminating the Kowa promotion agreement means Arcutis must now navigate the massive primary care and pediatric markets alone, requiring increased SG&A investments.
While nominal growth is strong, the 2026 guidance implies ~31% YoY growth, a significant deceleration from the 123% YoY growth achieved in FY25.
⚖️ Verdict: 🟢
Bullish. The company is executing flawlessly on its core strategy, converting topical steroid prescriptions to ZORYVE. Reaching sustainable profitability significantly de-risks the investment.
Key Themes
Displacing the Topical Steroid Market
The core macro narrative remains intact: ZORYVE is successfully capitalizing on the 'seismic shift' away from long-term topical corticosteroid use. The 84% YoY revenue growth in Q4 demonstrates that clinicians are actively altering standard-of-care practices, converting the ~17 million annual steroid prescriptions into recurring ZORYVE volume.
Medicare Access Breakthrough
Management announced a major payer victory: securing Medicare access beginning in January 2026. Approximately one in three Medicare patients now have non-preferred access to ZORYVE. In prior quarters, management cited IRA-related payer disruptions as a headwind for Medicare Part D; resolving this unlocks a massive, previously restricted demographic.
Kowa Partnership Termination Shifts Risk Internally
Arcutis mutually terminated its promotion agreement with Kowa (effective Jan 2026), shifting responsibility for the primary care and pediatric segments to an expanded internal sales force. In prior quarters, management admitted Kowa's ramp was slow. While internalizing this effort allows for better control, it introduces significant execution risk in changing the habits of non-specialists.
Pediatric Label Expansions Expanding TAM
Pediatric indications are functioning as a crucial growth multiplier. ZORYVE cream 0.05% was launched for ages 2-5 in October 2025. An sNDA is now accepted for plaque psoriasis down to 2 years of age (June 2026 PDUFA), and positive Phase 2 data in infants (3-24 months) will lead to another sNDA in Q2 2026.
SG&A Expense Re-Acceleration
To support the internal sales force expansion and the absorption of the Kowa territories, SG&A expenses surged 37% YoY to $79.0M in Q4 (up from $62.4M in Q3). While revenue growth outpaced this increase, investors must monitor whether this elevated spend structuralizes and threatens the newly established operating margins.
ARQ-234 Pipeline Advancement
On the innovation front, Arcutis is preparing to enroll the first patient in a Phase 1 study of ARQ-234 in Q1 2026. This novel fusion protein and CD200R agonist represents the company's leap into biologics for atopic dermatitis. Given competitor Eli Lilly previously discontinued a drug with a similar target, early clinical data here will be heavily scrutinized.
Other KPIs
Reversing decisively from a history of cash burn. Achieved exactly on the accelerated timeline management promised in Q3. This confirms the company's ability to self-fund future pipeline developments and eliminates dilution risk.
Accelerating from $14.5M in 24Q4. The increase is driven by higher clinical development and medical affairs costs, notably the infant atopic dermatitis trials and preparations for the ARQ-234 Phase 1 biologic study.
Stable/Improving. Management noted that the 29% sequential revenue growth was driven not just by unit volume, but also by improved GTN pricing, suggesting that payer rebates and copay assistance programs are normalizing efficiently.
Guidance
Decelerating percentage growth, but highly accretive absolute dollar growth. The midpoint ($487.5M) implies a 31% YoY increase from FY25's $372.1M. This is a deceleration from the 123% growth seen in FY25, but represents a $115M nominal increase and an upward revision from prior guidance of $455-$470M.
Key Questions
Kowa Transition Costs
With the termination of the Kowa agreement, how much of the Q4 SG&A increase ($79M) is a permanent structural addition for the new internal primary care sales team, versus one-time transition costs?
Q1 Gross-to-Net Headwinds
Historically, Q1 suffers from deductible resets. With the addition of Medicare Part D access starting in January 2026, will the Q1 gross-to-net headwind be more severe this year compared to historical patterns?
ARQ-234 Clinical Endpoints
As the Phase 1 trial for ARQ-234 begins enrollment, what specific early biomarkers will give you confidence that your engineered fusion protein will succeed where Eli Lilly's CD200R monoclonal antibody failed?